Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

摘要: Background & Aims Anemia is a common adverse effect of telaprevir (TVR) in combination with pegylated interferon (PegIFN)α and ribavirin (RBV) therapy. It occurs at higher incidence the TVR relative to PegIFNα RBV alone. We herein evaluate baseline on-treatment predictors development severe anemia by chronic hepatitis C virus (HCV) patients receiving TVR-based triple Methods This prospective, multicenter study consisted 292 (median age: 62years) infected HCV genotype 1. All received 12weeks 24weeks PegIFNα2b RBV. The definition during antiviral treatment hemoglobin (Hb) Results 101 (34.6%) developed period. Multivariable logistic regression analysis possible pretreatment extracted Hb p =0.0013), estimated glomerular filtration rate 2 (HR, 1.83; =0.0265), inosine triphosphatase (ITPA) CC (rs1127354) 2.91; =0.0024). For ITPA (n=227), multivariable level week 0.96; =0.0085) initial four weeks weight-adjusted 1.05; =0.0281). Conclusions remains risk for all treated However, polymorphism useful predicting will be helpful management treatment.